Research programme: tumour necrosis factor-alpha inhibitor antibodies - Numab/TillottsAlternative Names: Anti-TNF therapy - Numab/Tillotts; Antibody-based inflammatory bowel disease therapeutics - Numab/Tillotts; TNF-alpha blockers - Numab/Tillotts; TNF-α inhibitor antibodies- Numab/Tillotts; Tumour necrosis factor-alpha blockers - Numab/Tillotts
Latest Information Update: 23 Jun 2015
At a glance
- Originator Numab
- Developer Numab; Tillotts Pharma
- Class Antibodies
- Mechanism of Action Tumour necrosis factor alpha inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Inflammatory bowel diseases